Clinical Study

Related by string. * clinicals . CLINICAL . clinical . Clinicals : Phase III clinical trials . Phase III clinical . Phase 2b clinical . placebo controlled clinical trials . Clinical Excellence NICE . Phase III Clinical Trial / studying . Studying . STUDY . studys . study . STUDYING : Pre Feasibility Study . Study Shows . Case Study . Study Reveals . Study Confirms * Clinical Study Shows *

Related by context. All words. (Click for frequent words.) 78 Clinical Trial 76 Phase III Clinical Trial 76 Phase III Trial 75 Pivotal Trial 75 Clinical Trial Results 74 Clinical Trial Evaluating 74 Completes Enrollment 73 II Clinical Trial 73 Phase IIb Trial 73 Pivotal Study 72 Study Evaluating 72 Pivotal Phase III 72 Drug Candidate 71 Receives Orphan Drug Designation 71 Phase 2b Clinical Trial 71 Phase IIb Clinical Trial 71 Preclinical Data 70 Controlled Study 70 Meets Primary Endpoint 70 Patient Enrollment 70 Phase 2b Study 70 First Patient Enrolled 70 Completes Patient Enrollment 70 Patients Treated 69 FDA Accepts 69 Presents Positive 69 Investigational Compound 69 Presents Preclinical Data 69 Pivotal Trials 69 Phase IIa Clinical Trial 69 FDA Approves 68 Demonstrates Positive 68 Pivotal Clinical Trial 68 Improves Survival 68 Dose Ranging Study 68 Well Tolerated 68 Long Term Efficacy 68 Patients Treated With 68 Clinical Efficacy 68 Phase III Clinical Trials 68 Phase 2b Trial 68 Present Preclinical Data 68 Oral Fingolimod 68 Prospective Randomized 68 Files IND 68 Trial Evaluating 68 FDA Clears 67 Monotherapy 67 Initiate Clinical Trial 67 Phase 2a Clinical Trial 67 Randomized Clinical Trial 67 Initiates Phase 67 JAK Inhibitor 67 Pharmacokinetic Study 67 Metastatic Melanoma 67 Pivotal Phase 67 Preclinical Study 67 Study Showed 67 Autologous Stem Cell Transplantation 67 Initiates Clinical Trial 67 First Patient Treated 67 Initiates Phase II 67 Adjunctive Therapy 67 Phase 2a Trial 67 Investigational Drug 67 Relapsing Multiple Sclerosis 67 Patients Enrolled 67 Advanced Melanoma 67 Granted Orphan Drug 67 Successfully Completes Phase 67 Study Demonstrates 66 Non Invasive 66 Prolongs Survival 66 Combination Therapy 66 Anti Tumor Activity 66 Adjuvant Treatment 66 Receives FDA Clearance 66 Previously Treated 66 Severe Sepsis 66 Hepatocellular Carcinoma 66 Phase III Pivotal 66 Initiate Phase 66 Single Dose 66 Protease Inhibitor 66 Universal Flu Vaccine 66 Initiates Clinical 66 Combination Treatment 66 Investigational Agent 66 NDA Submission 66 Phase III Trials 66 Completes Patient Enrolment 66 IND Filing 66 Demonstrates Significant 66 Initiates Phase III 66 Osteoporosis Drug 66 IND Application 66 Novel Oral 66 Clinical Evaluation 66 Hemodialysis Patients 66 Postmenopausal Women 65 Combination REOLYSIN R 65 Randomized Study 65 Antitumor Activity 65 Receives Positive Opinion 65 Rheumatoid Arthritis Patients 65 Lung Cancer Trial 65 FDA Approvals 65 Novel Antibiotic 65 Shows Promising 65 Phase 1b Clinical Trial 65 Complicated Skin 65 Positive Opinion 65 Adjuvant Therapy 65 Placebo Controlled Trial 65 Monoclonal Antibody 65 Initiates Enrollment 65 Antiviral Activity 65 Vaccine Adjuvant 65 Clinical Study Shows 65 Demonstrates Potent 65 Randomized Controlled 65 Controlled Trial 65 Bosutinib 65 Dose Escalation Study 65 Patent Covering 65 FDA Approval 64 Submits NDA 64 Receives Approvable Letter 64 Appears Safe 64 Significantly Improved 64 Heart Failure Patients 64 Prostate Cancer Vaccine 64 Shows Promise 64 Acute Ischemic Stroke 64 Confirmatory Phase 64 Unfractionated Heparin 64 Receives Orphan Drug 64 Acute Myocardial Infarction 64 Improves Outcomes 64 Patients Undergoing 64 Randomized Double Blind 64 IIa Clinical Trial 64 Pafuramidine 64 Is Well Tolerated 64 Clinical Outcome 64 Patient Enrolment 64 Topline Results 64 Patients Suffering 64 Commences Phase 64 Pulmonary Arterial Hypertension 64 Augment TM 64 Proves Effective 64 Demonstrated Significant 64 Randomized Phase 64 Pooled Analysis 64 Newly Diagnosed Multiple Myeloma 64 Overactive Bladder 64 Receives Milestone Payment 64 Eluting Stent 64 Double Blind Placebo 64 Mylan Receives Approval 64 Oral Calcitonin 64 Dose Escalation 64 HCV Protease Inhibitor 64 Chronic Hepatitis C 64 Lupus Drug 64 Osteoporosis Treatment 64 Randomized Double Blind Placebo 64 Announces FDA Clearance 63 Diabetic Patients 63 Drug Shows Promise 63 Chronic Hepatitis B 63 Prostate Cancer Patients 63 Plaque Psoriasis 63 Shows Efficacy 63 Confirms Efficacy 63 Small Molecule 63 Regenerative Cells 63 Arthritis Drug 63 Significantly Improves 63 Metastatic Colorectal Cancer 63 FOLOTYN ® 63 Ischemic Stroke 63 Platelet Inhibition 63 Solid Tumors 63 Demonstrates Efficacy 63 First Patient Dosed 63 Phase IIa Trial 63 Malaria Vaccine 63 Tolerability 63 Meta Analysis 63 Stem Cell Treatment 63 Treatment Naïve Patients 63 Interferon Alpha 63 Renal Cell Carcinoma 63 Initiates Clinical Trials 63 Disease Progression 63 Phase Ib Clinical Trial 63 Infected Patients 63 Efficacy Trial 63 Pharmacokinetics PK 63 Receives Marketing Authorization 63 Drug Eluting Stent 63 Versus Placebo 63 Phase IIIb 63 Cutaneous T 63 Cancer Treatments 63 Node Positive 63 Fast Track Status 63 Survival Benefit 63 Cardiovascular Events 63 Anti Tumor 63 Statin Therapy 63 Improve Survival 63 Safinamide 63 Initiates Phase 2b 63 Lung Cancer Drug 63 Generic Version 63 Files Investigational 63 Plus Ribavirin 63 Inhaled Insulin 63 Effectively Treats 63 Patients Receiving 63 Announces Publication 63 Kinase Inhibitor 63 Liver Cancer 63 Metastatic Prostate Cancer 62 Chronic Heart Failure 62 Treating Heart Failure 62 Significantly Reduces 62 FDA Okays 62 Advanced Renal Cell 62 Therapeutic Vaccine 62 Dual Antiplatelet Therapy 62 Achieves Primary Endpoint 62 Data Suggest 62 Sustained Efficacy 62 Glatiramer Acetate 62 Initiated Phase 62 Gastric Cancer 62 Biomarker Study 62 Gout Drug 62 Resistant Hypertension 62 Receptor Agonist 62 Treatment Experienced 62 JAK2 Inhibitor 62 Hsp# Inhibitor 62 Hypertensive Patients 62 Multicenter Study 62 Investigational Treatment 62 Anticancer Activity 62 Expanded Indication 62 Randomized Double blind 62 Announces Positive 62 Randomized Controlled Trials 62 Diabetic Nephropathy 62 Randomized Clinical Trials 62 Transdermal Patch 62 Osteoarthritis Patients 62 FDA Clearance 62 Cholesterol Drug 62 Venous Thromboembolism 62 Low Dose 62 Efficacy Results 62 Advanced Prostate Cancer 62 Dupuytren Contracture 62 Breast Cancer Treatment 62 Advanced Colorectal Cancer 62 Cardiovascular Outcomes 62 Migraine Drug 62 Multiple Ascending Dose 62 Neoadjuvant Chemotherapy 62 Commence Phase 62 Recombinant Human 62 Prostate Cancer Treatment 62 Enrolling Patients 62 Metabolic Efficiency 62 Collaborators Present 62 Benign Prostatic Hyperplasia 62 Demonstrates Sustained 62 Improved Survival 62 Randomized Phase II 62 Weight Loss Drug 62 Phase IIIb study 62 Postmenopausal Osteoporosis 62 Personalized Immunotherapy 62 Inhalation Solution 62 Intravenous Formulation 62 Patent Issued 62 HDAC Inhibitor 62 Treated Patients 62 fosbretabulin 61 Dose Response 61 Pivotal Phase II 61 PRN FDA Approves 61 Sapacitabine 61 Clinical Trial Data 61 Adjuvant Chemotherapy 61 Melphalan 61 Microplasmin 61 Fondaparinux 61 Pediatric Patients 61 Phase III Pivotal Trial 61 Bivalirudin 61 Initiate Phase III 61 Commercialize 61 Rotavirus Vaccine 61 Initiates Dosing 61 Radical Prostatectomy 61 Novel Inhibitor 61 Treating Chronic 61 topically applied SEPA 61 Elderly Patients 61 Ofatumumab 61 Statistically Significant 61 Reports Preclinical Data 61 Treatment Naive 61 Inhibits 61 Inflammatory Arthritis 61 Aneurysm Repair 61 Successfully Treats 61 Schizophrenia Drug 61 Carboplatin Paclitaxel 61 Enrolls First 61 Myelodysplastic Syndromes 61 Nicotine Vaccine 61 Epilepsy Drug 61 Parathyroid Hormone 61 dose escalation clinical 61 Metabolic Disease 61 Subgroup Analysis 61 Therapeutic Antibody 61 Therapeutic Efficacy 61 Peginterferon Alfa 2a 61 Relapsed Multiple Myeloma 61 Treatment Naive Patients 61 Receives Fast Track 61 Develop Novel 61 Blood Thinner 61 Relapsed Refractory 61 Seasonal Influenza Vaccine 61 Multicenter 61 Antiviral Therapy 61 Randomized Trials 61 Presents Positive Preclinical 61 Kidney Function 61 Bazedoxifene 61 Shows Promise Against 61 Teva Provides Update 61 Systemic Delivery 61 Cholesterol Lowering Drug 61 Treatment Naïve 61 Multiple Myeloma Patients 61 Myocardial Infarction 61 Tezampanel 61 Reports Positive 61 Presents Preclinical 61 Bone Morphogenetic Protein 61 Psoriasis Drug 61 Anti Inflammatory Drug 61 Safety Tolerability 61 Therapeutic Potential 61 Rheumatoid Arthritis Drug 61 Surgical Mesh 61 Efficacious 61 Methylnaltrexone 61 Polymerase Inhibitor 61 Zenvia Phase III 61 Combination Clinical Trial 61 Recurrent Breast Cancer 61 RNAi Therapeutics 61 Brentuximab Vedotin SGN 61 Disease Modifying 61 TM Drug Eluting 61 Fungal Infections 61 Phase III multicenter 61 Clinical Trials 61 Oral Cladribine 61 Completes Dosing 61 Hormone Refractory Prostate Cancer 60 Balloon Angioplasty 60 Significant Efficacy 60 Placebo Controlled Study 60 Anti CD# Antibody 60 Humanized Anti 60 Testosterone Gel 60 Announces Initiation 60 Subcutaneous 60 Breast Cancer Recurrence 60 Sign Licensing Agreement 60 Sipuleucel T 60 Treatment Resistant 60 Treatment Reduces 60 Anti Clotting Drug 60 Trodusquemine MSI 60 Mycophenolate Mofetil 60 Receives Approval 60 Non Inferiority 60 Proven Effective 60 Successfully Treated 60 Randomized Controlled Trial 60 Antitumor 60 Topical Treatment 60 Medoxomil 60 Contrast Agent 60 Endovascular Treatment 60 oral prodrug 60 IIa clinical 60 HER2 Positive Breast Cancer 60 Vascular Disrupting Agent 60 Pandemic Influenza Vaccine 60 Protein Expression 60 Drug Fails 60 Knee Osteoarthritis 60 Endeavor Drug Eluting 60 Taro Receives 60 INSPIRE Trial Phase III 60 Radiofrequency Ablation 60 Hepatitis B Vaccine 60 Collaborators Publish 60 Spectrum Pharmaceuticals Announces 60 Gene Mutation 60 Immunosuppression 60 Bird Flu Vaccine 60 Submits Application 60 Cell Lymphoma 60 Advanced Pancreatic Cancer 60 Therapy Evaluation 60 Investigational Oral 60 Refractory Angina 60 Lupus Nephritis 60 Mouse Model 60 Observational Study 60 Hypercholesterolemia 60 RNAi Therapeutic 60 vapreotide acetate 60 Study Validates 60 Immunomedics Announces 60 Truvada tablets 60 Sirolimus Eluting Stent 60 Reduced Risk 60 Eculizumab 60 Quadrivalent 60 Multicenter Trial 60 Dose Ranging 60 Interferon Gamma 60 Kidney Transplant Patients 60 Phase 1b trial 60 Schizophrenia Treatment 60 Peginterferon Alfa 2b 60 Reveals Positive 60 Colorectal Cancer Patients 60 Antipsychotic 60 Begins Dosing 60 Vascular Grafts 60 Submits Response 60 Phase Ib II 60 ISTODAX ® 60 Inhaled Liposomal Ciprofloxacin 60 Zoledronic Acid 60 Diabetic Foot Ulcer 60 Cypher Sirolimus 60 Acute Attacks 60 Drug Eluting 60 Treatment Regimen 60 Drug Resistant 60 Castration Resistant Prostate Cancer 60 Total Knee Arthroplasty 60 Phase 2a Study 60 Stent Restenosis 60 Immunogenicity 60 Preclinical Models 60 Peginterferon 60 pralatrexate injection folate analogue 60 Kidney Transplants 60 Gets FDA Clearance 60 investigational humanized monoclonal antibody 60 Shows Statistically Significant 60 Liver Failure 60 Less Invasive 60 Prospective Multicenter 60 Slows Progression 60 Stent Implantation 60 Tiotropium 60 Replacement Therapy 60 Ranolazine 60 Cell Transplants 60 Prognostic Significance 60 Fixed Dose 60 Adverse Event 60 Anticoagulation 60 Prophylactic Treatment 59 Systemic Lupus Erythematosus SLE 59 By JENNIFER LEARN 59 dual endothelin receptor antagonist 59 Submits Supplemental 59 Smallpox Vaccine 59 Renin Inhibitor 59 Renal Impairment 59 Relapsing Remitting Multiple Sclerosis 59 Phase IIa trial 59 phase IIb trial 59 Naive Patients 59 Pharmacodynamics 59 Renal Cancer 59 Molecular Diagnostic Test 59 Stent Thrombosis 59 Significantly Reduced 59 Tumor Response 59 Endovascular Graft 59 Bone Graft 59 Nymox NX 59 Tyrosine Kinase Inhibitor 59 Hormone Therapy 59 Anticancer Drug 59 NICE Recommends 59 Malignant Melanoma 59 Beneficial Effects 59 Diabetic Neuropathy 59 ORLive Presents 59 Tesetaxel 59 Long Term Outcomes 59 Golimumab 59 IL# PE#QQR 59 Pharmacokinetic 59 Phase 1a clinical 59 Parenteral Nutrition 59 Drug Eluting Coronary Stent 59 Phase Ib clinical trials 59 Acute Decompensated Heart Failure 59 Patient Accrual 59 topically administered 59 Liposomal 59 Bucindolol 59 VIVUS Announces 59 Kidney Transplant Recipients 59 Submits Biologics License Application 59 R lenalidomide 59 Vitro Activity 59 Demonstrates Potential 59 Phase Ib clinical 59 Suppresses 59 Antiepileptic Drug 59 Receives Patent 59 Preclinical Efficacy 59 Fibrin Sealant 59 Cancer Vaccine 59 Submits IND 59 Lowers Risk 59 Hematological Cancers 59 Immunotherapeutic 59 Surgical Treatment 59 Unstable Angina 59 Progenitor Cells 59 Fracture Risk 59 NAVISTAR R 59 Renal Artery 59 number NCT# ClinicalTrials.gov 59 Synthetic Peptide 59 Novel Therapeutic 59 Aliskiren 59 Tolvaptan 59 Vaccine Candidate 59 Increased Risk 59 Begin Clinical Trials 59 Arterial Disease 59 Dendritic Cells 59 ORENCIA ® 59 Induces 59 Sangamo BioSciences Announces 59 Brain Metastases 59 Novel Treatments 59 dependent kinase inhibitor 59 Orally Active 59 Initiate Phase II 59 Researchers Identify 59 controlled dose escalation 59 TO AVOID PREGNANCY WHILE 59 include Phenoptin TM 59 Glaucoma Treatment 59 Extended Release 59 Viral Suppression 59 Randomised Controlled Trial 59 Milestone Payment 59 Emerging Therapies 59 PEGylated anti 59 Hepatitis C Genotype 59 Breast Cancer Patients 59 Receives CE 59 Announces Presentation 59 Liver Metastases 59 Archexin 59 Gene Variants 59 Prevent Stroke 59 Phase 2a clinical 59 Oral Interferon 59 DIRECT Trial 59 Announces Poster Presentations 59 Ambulatory Blood Pressure 59 Invasive Breast Cancer 59 Tuberculosis Vaccine 59 methylnaltrexone bromide 59 Drug Eluting Stents 59 Insulin Resistance 59 ALN TTR# 59 Elagolix 59 PEGylated Fab fragment 59 MEK Inhibitor 59 Autoimmune Diseases 59 Systematic Review 59 VIVUS Qnexa 59 Soft Tissue Sarcoma 59 Transdermal System 59 Beta Blocker 59 Controlled Clinical Trial 59 Attenuates 59 Carotid Stenting 59 See CLINICAL PHARMACOLOGY 59 SUTENT ® 59 GATTEX TM 59 Dialysis Patients 59 Estrogen Therapy 59 Adalimumab 59 Antibody Drug Conjugate 59 Percutaneous Tibial Nerve Stimulation 59 TRANSDUR ™ 59 CB2 selective receptor agonist 59 Left Ventricular 59 Adverse Effects 59 Orphan Status 59 Announce License Agreement 59 Generic Versions 59 Heart Transplant Recipients 59 k Clearance 59 ENDEAVOR IV 59 Transdermal Delivery 59 Epoetin Alfa 59 lexidronam injection 59 Implantable Device 58 Oral Anticoagulant 58 Eluting Coronary Stent System 58 PROSTASCINT R 58 Early Relapsing Multiple 58 Metabolic Disorder 58 Romiplostim 58 Aflibercept 58 Stem Cell Transplants 58 CHMP Opinion 58 Carotid Stent 58 TB Vaccine 58 Bladder Cancer 58 Randomized Evaluation 58 Augment ™ 58 Multicenter Randomized 58 Factor Xa Inhibitor 58 Patient Outcomes 58 Multicentre 58 Hormone Receptor Positive 58 Treatment Naive HIV 58 Telaprevir VX 58 Bone Mineral Density 58 Tesamorelin 58 Acute Pain 58 Levoleucovorin 58 Placebo Controlled 58 sulodexide 58 #-# Full Text 58 Receives CE Marking 58 Degarelix 58 Chronic Lymphocytic Leukemia 58 Iluvien ® 58 Study Proves 58 Acute Coronary Syndromes 58 Newly Diagnosed 58 miconazole Lauriad ® 58 Tigecycline 58 Dose Finding 58 REG2 58 Critical Limb Ischemia 58 Resubmission 58 Bone Metastases 58 Pegylated Liposomal Doxorubicin 58 Interferon Beta 58 Severe Asthma 58 Tablet Formulation 58 Interferon Alfa 58 Anticancer Agent 58 Invasive Fungal Infections 58 Oral Insulin Capsule 58 CCX# B 58 Reperfusion Injury 58 Aortic Valve Replacement 58 Zemiva ™ 58 Post Operative 58 Partial Onset Seizures 58 multicenter Phase III 58 Randomised 58 Glufosfamide 58 Systemic Sclerosis 58 Endometrial Cancer 58 Begins Clinical Trial 58 CYPHER R Sirolimus Eluting 58 Oral Mucositis 58 Irinotecan 58 Metastatic Renal Cell Carcinoma 58 Nuclear Receptors 58 Companion Diagnostic 58 Study Shows Benefits 58 Robotic Assisted 58 Osteoporosis Drugs 58 Previously Untreated 58 Immunosuppressant 58 Intervention Trial 58 Rheumatoid Arthritis 58 Catheter Ablation 58 clinical trial 58 Hematological Malignancies 58 ALN TTR 58 Minimally Invasive Treatment 58 Novel Mechanism 58 diarrhea predominant irritable 58 BRIM2 58 Announce Collaboration Agreement 58 C1 Inhibitor 58 Randomized Placebo Controlled Trial 58 Gene Therapy Trial 58 Potent Inhibitor 58 Chemoradiation 58 Luveniq 58 Autologous 58 KRN# 58 Localized Prostate Cancer 58 Supplemental Biologics License Application 58 Desvenlafaxine Succinate 58 Ocrelizumab 58 Treat Anemia 58 Respiratory Virus 58 Contrast Enhanced 58 Cocaine Addiction 58 PDX pralatrexate 58 Gene Variant 58 Chronic Renal Failure 58 peripherally acting 58 Lanthanum Carbonate 58 Marketing Authorisation Application 58 Cardiac Resynchronization 58 ENESTnd 58 Vascular Inflammation 58 Antiplatelet 58 Eszopiclone 58 Inhaled Corticosteroids 58 identifier NCT# 58 Cancer Therapies 58 Renal Function 58 FDA Panel Recommends 58 Study Evaluates 58 Cannabinor 58 ARIXTRA R 58 Atypical Hemolytic Uremic Syndrome 58 phase IIa clinical 58 Extended Release Capsules 58 Pharmaceuticals Initiates 58 Immune Responses 58 Endothelial Cells 58 APEX PD 58 Balloon Catheter 58 Laryngeal Cancer 58 Coronary Stent 58 Reduces Mortality 58 Blood Pressure Drug 58 Cellular Immunotherapy 58 pharmacokinetic PK 58 Chronic Myeloid Leukemia 58 Radiofrequency Ablation RFA 58 ThermoDox R 58 Carotid Endarterectomy 58 Demonstrate Significant 58 multicenter phase 58 Risk Stratification 58 phase IIb 58 Intervention Effectiveness 58 PROMUS R 58 Slow Progression 58 Capsules CII 58 Receptor Antagonist 58 Advanced Solid Tumors 58 dose escalation trial 58 Tolerability Study 58 Phase IIa clinical 58 Denufosol 58 Phase IIa 58 Phase 1a 58 Panzem R 58 Pharmacokinetics 58 MKC# MKC# PP 58 Kamada AAT 58 Feasibility Trial 58 Immunologic 58 Clinical Outcomes 58 Anturol TM 58 CT Angiography 58 Thrombolysis 58 Medullary Thyroid Cancer 58 Commercialize Novel 58 Orphan Drug Status 58 Neuroprotective Effects 58 Embolic Protection 58 Anticoagulant 58 Allergic Rhinitis 58 Obese Patients 58 Cardiotoxicity 58 Clinical Validation 58 BioElectronics Announces 58 Prostate Surgery 58 ONGLYZA TM 58 Therapy Improves 58 Commences Phase III 58 TRANSDUR ® 58 Aurora Kinase 58 Receives SFDA Approval 58 Restenosis 58 Receives Complete Response 57 Angiogenic 57 Vaccine Trial 57 PANVAC VF 57 Enoxaparin 57 Phase IIB 57 HER2 Positive 57 Non Responders 57 dyskinesia PD LID 57 Guidelines Recommend 57 Peripheral Arterial 57 Hepatitis C Patients 57 Vicriviroc 57 Blinatumomab 57 Topical Gel 57 Stem Cell Transplant 57 rALLy clinical trial 57 Bosentan 57 BOLDER II 57 Romidepsin 57 dasatinib Sprycel ® 57 Diabetic Macular Edema 57 Antisense Drug 57 Oral Spray 57 Aggressive Reduction 57 aripiprazole Abilify 57 hyperphenylalaninemia HPA due 57 signal detection CTSD 57 Ozarelix 57 Neulasta ® 57 Files Patent Application 57 Iluvien TM 57 Predict Risk 57 Showed Significant 57 Improve Outcomes 57 Efficacy Study 57 XIENCE V Stent System 57 Induction Therapy 57 Peripheral Artery Disease 57 Genetic Tests 57 FDA Approves Drug 57 Influenza Vaccine 57 ST Elevation Myocardial 57 Oral Presentation 57 Orthostatic Hypotension 57 Nebulized 57 PHASE III 57 Liberte TM 57 Hepatic Encephalopathy 57 Randomised Trial 57 Antiviral Drugs 57 phase IIa 57 Efficacy 57 dihydrochloride Tablets 57 Refractory Hodgkin Lymphoma 57 VIVITROL ® 57 Shown Effective 57 Phase Ib 57 Phase 2b study 57 Achieves Milestone 57 Oral Insulin 57 Hospital Acquired Pneumonia 57 Enzastaurin 57 Elevated Levels 57 Adenoma 57 PROVENGE ® 57 Patency 57 Antigen Specific 57 BioSante Pharmaceuticals Announces 57 Aortic Valve 57 Myocardial Infarction Study 57 Phase III HEAT 57 Virtual Colonoscopy 57 investigational antiplatelet agent 57 Gentium Announces 57 Cognitive Impairment 57 Atopic Dermatitis 57 Prodrug 57 Bare Metal Stents 57 Regenerative Cell 57 Exclusive License 57 relapsing multiple sclerosis 57 Reduces Pain 57 Researchers Develop 57 Prostate Biopsy 57 Intracranial Aneurysms 57 RE MODEL 57 Develops Novel 57 Radiation Induced 57 J Clin 57 investigational oral inhibitor 57 Phase 1b clinical trials 57 Diabetic Neuropathic Pain 57 MyVax R 57 Sirolimus Eluting 57 Anticancer Compound 57 STELARA TM 57 Endovascular Valve Edge 57 Artificial Pancreas 57 Dasatinib 57 Apaziquone 57 Inhibits Growth 57 Novel Method 57 Treat Heart Failure 57 Wound Dressing 57 Earns Milestone Payment 57 Hepatitis C Virus 57 Blood Pressure Lowering 57 FDA Approvable Letter 57 Gastrointestinal Cancers 57 Cardiogenic Shock 57 Valsartan 57 Uterine Fibroid Embolization 57 Therapy Reduces 57 Licenses Novel 57 Xcytrin R 57 Left Ventricular Dysfunction 57 ELADUR ™ 57 Septic Shock 57 Epratuzumab 57 Antihypertensive 57 EVEREST II 57 adalimumab Humira 57 phase Ib 57 Synta Announces 57 SYCREST 57 Osteoarthritis Pain 57 Cervical Cancer Vaccine 57 Myelodysplastic Syndrome MDS 57 Blocked Arteries 57 Cell Proliferation 57 Endurant 57 Pemphigus Vulgaris 57 Drug Coated Stents 57 Study Casts Doubt 57 Glucose Control 57 Ecallantide 57 Carotid 57 Urinary Incontinence 57 Holds Promise 57 Myocardial Ischemia 57 Cervical Dysplasia 57 Recombinant Protein 57 Pralatrexate 57 Neuroprotection 57 Ovarian Cancer Patients 57 Test Detects 57 Autoimmune Disease 57 Factor Receptor 57 Fabry Disease 57 LibiGel ® 57 Significant Improvement 57 Percutaneous Coronary Intervention 57 Inflammatory Markers 57 Cetrorelix 57 PKC# 57 Acute Stroke 57 Drug Eluting Stent System 57 Guidelines Issued 57 Tocilizumab 57 toenail onychomycosis 57 Androgen Independent 57 Kinase Inhibitors 57 Therapeutic Effects 57 Bevacizumab 57 multicenter randomized controlled 57 Avian Flu Vaccine 57 ID NCT# 57 Entereg TM 57 Pneumococcal Vaccine 57 phase IIIb 57 PDUFA Date 57 Mg Uk 57 DermaVir Patch 57 Phase III clinical 57 Bortezomib 57 MORAb 57 WorldHeart Announces

Back to home page